as for we important the announced Marek, our over month, probably you, you be call. the help notably Actuate afternoon to them past very read this on will many Therapeutics, with collaboration drug past today. over thank first AI engine XXXX everyone where We've good progress RADR and we to our of joining points advance their leveraging you the quarter candidate. for very a number morning; and a call quarter conference us Thank got
As leverages power Lantern our up opening we oncology Machine drugs and the oncology data repurpose of is our by doors of therapeutics. develop rescue drugs you the learning new using RADR, oncology cost, machine of transforming the approach. called the drug know changing by are Pharma internally believe pace, risk development that enabled the an to development We biopharma and to Learning company AI that platform developed driven
March the X.X of the the few that want highlight to and X I end end platform of pure and of by last well data billion as are few one are and with modeling rapidly prediction milestones understanding, accelerating as We multiple a companies billion cancer over notably to We the this surpassed critical. a achieved first of quarter. of AI RADR Most in based for clinical programs, multiple tumor of patient response April. proprietary stage our in play those platform AI key points our therapies. as biopharma growing campaign,
cancer We later an non-smokers LP-XXX with clinical Barnhart provide Phase our cell to call. for This X lung for the in FDA Dr. today's also non-small our trial update is in program on development submitted and updated plan LP-XXX. will an
the quarter, The brain we include expanded tumors LP-XXX in rhabdoid in for collaboration quarter Oncotarget non-small-cell Hopkins. cancer atypical being this ATRT indications in lung drug Johns also LP-XXX the work to and and ultra-rare tumor with pursued potential teratoid resistant in also During published lung for is pediatric indication cancer. was past while
hematologic from entirely molecule new our We new that pre-clinical to of are development exceptional very indications molecule. also initiated different XXX certain shown have cancers molecule an this LP-XXX, in and sensitivity that
our of molecules novo those strengthened use patent applications actually identifying intellectual to of that cover our patients, of filing ranging We aspects technology with property to over platform. to RADR methods de XX of fundamental the portfolio also from manufacturing,
team approach drug and our LP-XXX. and transparency the these one in process published used drug research two approach. being studies hallmark in think actually development driven central validate of our learning Bioinformatics in enabled how to Our of implemented BMC and further machine peer-reviewed Oncotarget data also provide data driven We development and that a on for was details RADR a is development
to potency we a DNA Very our the the damage Our cancers, power million including AACR neutrality. importantly XX, combination synthetic collaboration follow-on multi-year completed of very LP-XXX those bring the DNA can to personalization to damage Virtual in therapeutics that precision balance presented poster also in this and overexpression believe of conducted had to harness year. provides with of offering Georgetown we globally. innovate oncology the and of the scientists indications initially along examining was efficacy and that patients cancer sheet, a January significantly PTGRX in repair repair hope confers the a at strengthened increase That $XX our potentially that also us RADR poster dramatically execute path plan that and prostate potential with runway
cycle brought not you also but to and pace is the only listened about are drugs, product cost that to have the X.X growth passionately For to only way and every of fold at know that data a the has we development nearly of market, a represents changing use XX May industry. talks the smashed four-fold beginning the believe cost, my this increase do AI and billion over which with machine It to to growth and learning, is last since calls points those believe The prior RADR for oncology since now. year. earnings which the I curve absolutely of other
Let me this differently, very simply. put and
of X billion of a points This each monthly XXXX entirety We development required our the during curated biologically is to relevant first guide volume are drives that campaigns. cancer of roughly quarter. adding during pace the in drug information data month data the
to the billion are they Our of now data during to achieve end our voluminous, more billion are by year the track campaigns reaching we've are points X to expecting becoming XX smash of larger, which already and over becoming on and next goal this X billion reached, campaign. previous we're
help X-ING-XX also cancer platform, the functionality is arrangements own AI and equity opportunities leveraging soon, model to We pipeline for Actuate from opening and our on productivity potential Actuate's to this importantly, person expected the candidates. accelerate The is more development their acquire to keep a This that but able including yield earlier oncology also to our the data aspects start development biopharma and develop only focuses learning companies is candidate GSK-Xβ RADR and candidates, foreign and best-in-class rear drug of will collaborate in the innovative tremendous set pancreatic in cancer. collaboration pandemic X scale aspect our immediately. of we with Lantern large that accelerate that in RADR of expect the as inhibitor not with opportunity we in our methodology, oncology increasing more drug other to Exemplifying announced up Phase to clinical drug as trials, key and The kind at milestone are multiple now of insights effectively the we many investors. collaboration collaboration business to Most are to active Therapeutics knowledge today. and the machine teams collaborate locations.
milestones equity companies. asset. novel owned growing are to utilized already the by Actuate collaboration, the is will if Lantern in be future terms In We equity in collaboration fact upfront development developing generate it that jointly has will potentially of think property collaboration, receive leverage Therapeutics certain meeting started intellectual efforts. as form Pharma the the in this and of the Under will as this results the to additional conditions of a well way in great subject
improve RADR risk and mission Our market of and our bringing worldwide the oncology cancer to platform drug development, transform ultimately cost remains the the pace, impacting AI the capital ultimately compounds which faster significantly of to therapies for discovery power unleash to increased personalize and lives by same of reduced this patients and decreased the reduced ability our developed cost. may has and potential with personalize of with to which risk, accelerate RADR should be therapy. patient outcomes indication, the understanding to and and
make, and highly calls sequencing, I've and true about investor in computing power, drug healthcare talent biomarkers previous experiencing golden beginning aligned to and resources, living development genomics. a and medicine, medicine we're have in era analytics especially driven in solving in along to During is by spoken of relevant drug global complex where and reality. problems all algorithms, data, in data and responsive, demands with This an economic AI and availability of machine the development, a large is scale cloud age the of AI the along how on-demand acceleration especially with pool and of that earmarked approaches
and expanding partners. both oncology from we’ve in We on a our capabilities the standpoint, and of number programs development to are standpoint. of age grown golden active candidates awards our very, our also XXXX the the critical, risk but drug goal shots pipeline very X; those accelerate harnessing June of IPO, now from of from also have Since trends this
more can months public, XX have antibody we number than our impact We patterning that since initiating accretive goals, generate limited significantly to and also time to and the development an we’ve of for of even we an conjugate the the increased program. been doubled cancers of just increase now shots opportunities we In have opportunities licensing are potentially are amount drug giving in upside, on investors more on transactions. range of plus these
certain where particularly asset point is ATRT therapies, We us into This LP-XXX rare to are opening for important in there's massive the enable or into patients clinical by may bring This and improved fact to cancers we're note. areas other and as an markets cancers. directly to such ultra-rare need excited especially the certain ourselves. ultra-rare that
We in a for Kerry detailed protocol first-in-class the accounts geographies. are clinical high in Phase who potentially unaddressed trial LP-XXX, LP-XXX medical therapy a the for cancer targeting adenocarcinoma pipeline. Barnhart lung the will of our among begin update later anywhere our but cell non-small high review candidate in firmly type drug patients trial a growing, LP-XXX that cancer a advanced of candidate non-smokers, defined clinically approximately quickly histologically this to need call. XXXX, represents discuss combination lung certain and on about each lung drug XX% third cell Dr. Let's on small of actually molecule even spent quarter non-small unmet patient cases We population. X track and remain cell early billion in new for believe of more in for patient for this non-smokers. – globally that most non-small now this provide therapies drug is globally cancer treatment population. $X.X likely year – medical
that working studies various the With study an collaboration experience and for area therapy we therapeutic of of to prostate an more with their program of features in that is can disclosed Hopkins our active cancer. are currently respective the tumor LP-XXX Recall University active that drug and CNS now their in tumors we researchers glioblastoma and LP-XXX Georgetown a and to Johns in and cancer on pancreatic experience prostate leverage Moving LP-XXX across four a patient in the active of specific the LP-XXX business development our with knowledge candidates given so a including models indications with center, the is in among development collaborate population. leading cancer types. that’s evolving central area, with rapidly ATRT. in in
collaborations to for and additional collaboration we XXXX. begin clinical and clear and the prepare and believe action in of of indication We the for work clear is indication KOLs mechanism leading clinical genomic – that biomarker with a collaboration drug, We based being and need we leverage indications these can targeted or a in and patient to explore that potentially other months. the of The track their each respective Phase collaborations the at trials to additional continue a development done in model experience relevant remain gain trials of the have to on each announce from where coming this scope we our expect to and LP-XXX X candidates of opportunities and we insight, signature. development firmly these or institutions driving expertise, clinical
We will programs as in regular appropriate. to each of provide continue these updates
more there In as potentially note of as the the commercial of and colorectal. and companion or Xx important also used collaborations to certain each these there receive times and more in allow for done pancreatic, prostate, likely can efficient such cancer recent biomarker Toronto like it of a will University data development a we manner. cancers programs. Researchers that diagnostics a like this that clinical cancer ongoing very collaborations trials very more expect I thereby fact is to was quarter of in the lower publication we approvals. get In the all signature our signature that drug clearly a increase us defines notable the It’s five cancer Xx breast potential was in like to biomarkers the innovative guide serve fact of that to quarter to regulatory cancers was XXx, were have by cost a candidates. of other based to used effective help believe next These goals indicated validation in disease Xx and and of that Among the
cancer therapies. potent the drug that millions accelerating that driven relevant Georgetown in DNA a future trials save significantly benefits could our LP-XXX the robust pathways certain is while the highly for focused prostate personalization experience goal of development PTGRX the create the and example of to Ultimately dollars signature validating genetic to AI the in the and role prostate biologically the preparation on For of believe across to cancers. with Lantern’s clinical gene We make objective with allowing repair a the collaboration collaboration currently of more the is personalized treatment damage patients a of path of mutations approach costs, appropriate. drive commercialization and
robust to subtypes potential similar also Program LP-XXX therapy targeted of We further and development Fox government Igor being Center collaboration pancreatic at improve this the in have the pancreatic cancer. cancer, uses Chase LP-XXX agreement advances research a Cancer also XXX, for in This defriend with of the led survival. We option the a in collaboration open the more This personalized could signature. at that has up the Fox is Dr. gene Astsaturov believe pathway Therapeutics Chase. to to program Molecular by genetically
Hopkins part. the also primarily We agreement entirely a Rhabdoid in Johns is announced development ATRT Atypical SMARCBX in growing of the also new ATRT or by the fast research notably that ultra-rare either in tumors and of cancers or XXX with brain presents and collaboration deletion, Teratoid for marked tumors children.
be no in So patients a incidence that battle of for towards focus research on pediatric supports programs globally, in to prevalence for ATRT SMARCBXmutated all opportunity derived as They'll review a centers that ultimate one cancer highlighted LP-XXX with for U.S. the cancer research as it stage getting vitro is cancers disease studied many directing grant a This treatment more aggressive using and and are second the a the models. who therapy world cycle cancer brain incidents tumor we the work another cancer in the per category largest in biology of ATRT qualify a to has These collaborate This mechanisms to center Pharma. LP-XXX. voucher. precisely gives by for brain voucher combination Hopkins Hopkins AI new to the growing potential possible actually enhancing our of approximately milestone the receiving leading of in qualify types represent this cancers. FDA helping are successful X.X% for in us programs urgency brain Pediatric additional and in we such in forefront year. as brain potentially more rate one and vitro with establish was the of currently into a leveraged you the Lantern disease cancer value X.X% RADR Georgetown could effective self-evident, cancer to rare that are the this represent relevant in signature his insight innovative creating and by tumor drug allows done Oncologist cells children new Eric translational know career its that of designation. rare also Johns physiologically to affected approach particularly death early of We understand has driven with targets data platform. the Fox with treating the and tumors. to researchers of if can Hopkins, of course This by from for allows review the leading was studying That future designation, in is rarity If significant the believe pediatric precise molecules. cyclical approval, manner. these Pediatric creating pediatric medicine. would of and insight the guided Raabe, pediatric to children brain devoted Dr. priority unfortunately the Chase cause the actively patient and in the U.S. that's with research for use receives the
as Our of developing tens our we're rare or Also treatments ago, what ones our we such such evaluating. the it cancers of and published describing ultra-rare talks weeks published over of pancreatic just has in potential for for drug targeted as to non-small therapy. two clinical millions time other we where If our such ineligible LP-XXX, has currently the for different are published, dollars in who drug there's as cell a and a the team can about of research ATRT, years the accelerate to we derisk mission compress patients is forms resistance and the transform can clinical and one trials to other lung therapies save clear process. cancer or LP-XXX development drugs cancer manuscripts Oncotarget of need variety developed of for also efficacy also have models, that GBM,
cancer are is aren't very responding profile. goes very or that where a been LP-XXX complementary unique molecular this approach us eligible. with target patients therapy of non-smokers interesting longer again for are of we a Similarly very non-small cell LP-XXX have because lung different that For no a our targeted to subset targeting
EGFR genetically such targeted sets. have So don't XX%, only of alterations patient meaning, good all that or standard have that believe options those prognosis. ALK ALK patient that existing will as seeing about targetable inhibitors therapies very LP-XXX as current therapies. actually EGFR, There’s be developed work to effective potentially that without and in That defined close in XX% resistance not such to patients leaves could additional a those therapeutic class. care the and We
response and platform. to response for milestones tumors very together form We we uncovering importantly this advancing a of of that our show and link pre-clinically data drug. provide and this and portfolio our advancing signature therapies. capital occurring accomplished of genetic months is mechanism, that that to have approach, to responsive in we believed cancer potential but XXXX clinically driven to in the the guiding can mouse XXX also in achieve to cancers enhancing and public, tumor our terms predict and the past has be We’ve that are will lung believed is being and are of lunch value, usually portfolio, carcinoma KEAPX undrugable. RADR show co-occurring biomarkers drug XX that inhibits we’ve next believe AI that we a about a that team not we’ve multiple over KEAPX developed XXXX cases, of further unique KRAS In our the and Using find KRAS subgroups meaningful milestones. development aggressive in model from to be that now how working sufficient lung patient mutant in mutations amount shareholder rapidly benefit growth, those XX% new We show will and indications can now uncover can significant of LP-XXX xenograft only very
David. over hand for CFO I’ll quarter our to call results. Now or David first review the Margrave, financial a of
